Theranos, the disgraced blood testing startup once valued at $9 billion, broke all of its promises and “failed to meet the most basic quality standards and legal requirements” in its contract with Walgreen Co. That’s according to a scathing lawsuit (PDF) from the US drugstore giant, which owns neighborhood Walgreens.

The two companies had teamed up in 2012 to offer Theranos’ low-cost, finger prick-based blood tests to Walgreens’ customers in “Wellness Centers” that would be set up within Walgreens’ drugstores. According to the court documents, Theranos had spent two years wooing Walgreens into the deal, promising “disruptive” proprietary technology that would be of the highest quality and receive regulatory approval.

But the deal imploded and the relationship soured after media reports in late 2015 revealed problems with Theranos’ technology, testing standards and accuracy, and its dealings with regulators. In July of 2016, federal regulators levied hefty and unprecedented sanctions on Theranos after inspections found deficiencies that posed “immediate jeopardy” to patient health and safety. Regulators revoked the certification of one of Theranos’ labs and banned the company’s founder and CEO, Elizabeth Holmes, from the laboratory business for at least two years.

All the while, Walgreens alleges that Theranos: actively misled the company; didn’t live up to the quality and regulatory promises; kept Walgreens in the dark about problems; refused to answer questions as media reports came out about those problems; accused Walgreens of leaking information to the press; and asserted that Walgreens was the one that had breached their agreement.

Walgreens filed a lawsuit in federal court in Delaware last week, under seal. Today, a redacted version of the complaint was filed. Walgreens is seeking $140 million in damages, which is rumored to be about what the company invested in the agreement with Theranos.

In a statement, Theranos responded to the lawsuit, saying:

We are disappointed that Walgreens filed this lawsuit. Over the years, Walgreens consistently failed to meet its commitments to Theranos. Through its mishandling of our partnership and now this lawsuit, Walgreens has caused Theranos and its investors significant harm. We will respond vigorously to Walgreens’ unfounded allegations, and will seek to hold Walgreens responsible for the damage it has caused to Theranos and its investors,

Since regulators levied the sanctions, Theranos has switched its business strategy to device manufacturing. In August, Holmes unveiled the automated “miniLab,” which the company claims can perform a wide variety of blood tests.

Walgreens noted the business shift in its lawsuit. The company alleges that the shift provides further evidence that Theranos could not meet its agreement, which was dependent on Theranos running a clinical lab.

Though details of the two companies’ agreement were redacted from the released complaint, the court documents reveal more specifics about Theranos’ infamously secretive and evasive tactics. Walgreens alleges that Theranos actively withheld and hid letters and inspection reports from federal regulators. Walgreens also alleges that it only learned through media reports that Theranos had voided tens of thousands of tests—most of which involved Walgreens customers.

When Walgreens contacted Theranos about some of the negative media reports—which turned out to be accurate—Theranos representatives told Walgreens that the reports were “unfair,” “inaccurate,” and a “misleading portrayal of Theranos.”

The suit also reveals the extent to which Theranos may have misled early investors and prospective partners. Walgreens alleges that Theranos indicated it had approvals from the Food and Drug Administration—which it never had—and that its technology had been validated. In March of 2010, Theranos told Walgreens that its technology had been “comprehensively validated” over seven years by “10 of the 15 largest pharmaceutical companies”—a claim that’s hard to believe. Theranos went on to state that bio-pharma companies, “prominent research institutions, and US and foreign government health and military organizations” had already used the technology, as well.

In June of this year, Walgreens severed ties with Theranos and shuttered its Wellness Centers.